Edwards Lifesciences hit with $10 million penalty over JC Medical acquisition antitrust violations

RegulationCorporate Action
โดย Medical Device Network·Read original
Summary · why it matters

Edwards Lifesciences must pay a $10 million penalty to settle a court ruling that it violated antitrust law in its acquisition of JC Medical nearly two years ago. The US Federal Trade Commission filed a complaint revealing that Edwards acquired JC Medical for an upfront payment of $115 million and pledged an additional $25 million investment into Genesis Medtech, structuring the payments to avoid the Hart-Scott-Rodino Act threshold of $119.5 million and thereby skirt mandatory antitrust review. The FTC alleged that Edwards did not publicly announce the deal and purposefully avoided filing requirements, and the day after closing it entered an agreement to purchase JC Medical's key competitor JenaValve. JC Medical must pay $2 million, bringing the combined $12 million penalty to the largest ever for failing to make an HSR filing. Edwards must also establish an antitrust compliance program and designate an antitrust compliance officer.

Impact on stocks 1

Aging Population▼ · 1 stocks
Edwards Lifesciences Corp
EW
▼ NegativeRegulationrelevance

Edwards Lifesciences must pay $10 million penalty for antitrust violations in JC Medical acquisition, plus establish compliance program.

Off-coverage companies 2

Genesis MedtechPrivate▼ Negative
Regulationrelevance

Genesis Medtech must pay $2 million penalty as part of the antitrust settlement.

JenaValve TechnologyPrivate± Mixed
Competitionrelevance

JenaValve is mentioned as a key competitor that Edwards acquired after the JC Medical deal, but no direct impact on JenaValve itself is stated.

© 2026 MarketDXNews